Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa (Osilodrostat) in Patients With Cushing's Disease
The LINC 4 study demonstrated superiority of Isturisa (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week, double-blind, randomised phase (77% vs 8%, P Isturisa provided
Source: finanznachrichten.de